- Home
- Publications
- Publication Search
- Publication Details
Title
New Therapies for Advanced Thyroid Cancer
Authors
Keywords
-
Journal
Frontiers in Endocrinology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-05-22
DOI
10.3389/fendo.2020.00082
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
- (2019) Janice M. Mehnert et al. BMC CANCER
- Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial
- (2019) Sarah R. Brown et al. BMC CANCER
- The VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers
- (2019) Razelle Kurzrock et al. CLINICAL CANCER RESEARCH
- Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study
- (2018) Glenn J. Hanna et al. CLINICAL CANCER RESEARCH
- Immune landscape of papillary thyroid cancer and immunotherapeutic implications
- (2018) Kwon Joong Na et al. ENDOCRINE-RELATED CANCER
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
- (2018) Vivek Subbiah et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer
- (2018) Viswanath Gunda et al. INTERNATIONAL JOURNAL OF CANCER
- Differentiated Thyroid Cancer—Treatment: State of the Art
- (2017) Benedikt Schmidbauer et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013
- (2017) Hyeyeun Lim et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Erratum for “Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial”
- (2017) JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Synergistic activity of everolimus and 5-aza-2′-deoxycytidine in medullary thyroid carcinoma cell lines
- (2017) Giovanni Vitale et al. Molecular Oncology
- Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases
- (2017) Benjamin Bonhomme et al. THYROID
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?
- (2016) Bryan R. Haugen CANCER
- Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany
- (2016) Julia Wendler et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
- (2016) Iñigo Landa et al. JOURNAL OF CLINICAL INVESTIGATION
- Non-invasive follicular thyroid neoplasm with papillary-like nuclei: reducing overtreatment by reclassifying an indolent variant of papillary thyroid cancer
- (2016) David N Poller et al. JOURNAL OF CLINICAL PATHOLOGY
- Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
- (2016) Marcia S Brose et al. LANCET ONCOLOGY
- Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer
- (2016) Josiah E. Hutton et al. MOLECULAR & CELLULAR PROTEOMICS
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
- (2016) Bryan R. Haugen et al. THYROID
- Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer
- (2016) Eran Brauner et al. Oncotarget
- A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment
- (2015) Maria E. Cabanillas et al. CANCER
- PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises
- (2015) F. Massari et al. CANCER TREATMENT REVIEWS
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis
- (2015) Samira M. Sadowski et al. Oncotarget
- mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib
- (2015) Elyse K. Hanly et al. Oncotarget
- Molecular Targeted Therapies of Aggressive Thyroid Cancer
- (2015) Silvia Martina Ferrari et al. Frontiers in Endocrinology
- High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma
- (2015) Yueh-Min Lin et al. PLoS One
- Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
- (2014) S. M. Rothenberg et al. CLINICAL CANCER RESEARCH
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
- (2013) Kiyoshi Okamoto et al. CANCER LETTERS
- The Increase in Thyroid Cancer Incidence During the Last Four Decades Is Accompanied by a High Frequency ofBRAFMutations and a Sharp Increase inRASMutations
- (2013) Chan Kwon Jung et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
- (2013) Alan L. Ho et al. NEW ENGLAND JOURNAL OF MEDICINE
- RAS Mutations in Thyroid Cancer
- (2013) G. M. Howell et al. ONCOLOGIST
- Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAFV600E Mutation
- (2013) Kevin B. Kim et al. THYROID
- Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements
- (2012) D. N. Hayes et al. CLINICAL CANCER RESEARCH
- Follicular Adenoma and Carcinoma of the Thyroid Gland
- (2011) C. R. McHenry et al. ONCOLOGIST
- Anaplastic Thyroid Carcinoma: Pathogenesis and Emerging Therapies
- (2010) R.C. Smallridge et al. CLINICAL ONCOLOGY
- VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma
- (2010) Z Karaca et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Aggressive variants of papillary thyroid carcinoma
- (2010) Carl E. Silver et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Benefits of Thyrotropin Suppression Versus the Risks of Adverse Effects in Differentiated Thyroid Cancer
- (2010) Bernadette Biondi et al. THYROID
- Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors inBRAFMutant Thyroid Carcinoma Cells
- (2009) Paolo Salerno et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Association ofPTENgene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors
- (2008) Peng Hou et al. CANCER
- BRAFV600EMutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines
- (2008) Rebecca Leboeuf et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Highly Prevalent Genetic Alterations in Receptor Tyrosine Kinases and Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase Pathways in Anaplastic and Follicular Thyroid Cancers
- (2008) Zhi Liu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now